Cargando…

Recovery of Dementia Syndrome following Treatment of Brain Inflammation

AIM/BACKGROUND: This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jong-hoon, Choi, Su-hee, Lee, Chul Joong, Oh, Sang-suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011720/
https://www.ncbi.nlm.nih.gov/pubmed/32158462
http://dx.doi.org/10.1159/000504880
_version_ 1783496117271396352
author Lee, Jong-hoon
Choi, Su-hee
Lee, Chul Joong
Oh, Sang-suk
author_facet Lee, Jong-hoon
Choi, Su-hee
Lee, Chul Joong
Oh, Sang-suk
author_sort Lee, Jong-hoon
collection PubMed
description AIM/BACKGROUND: This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports, Mycobacterium leprae was a factor in reducing the incidence of Alzheimer's disease. Thus, we formed a hypothesis that if dapsone is administered to patients without leprosy but with MCI and the prophylactic effect of dementia syndrome is observed over a long period of time, we can determine whether dapsone can prevent the progression of MCI to dementia syndrome. If dementia does not occur after treating inflammation in brain cells while dementia develops after a certain long-term period (usually within 2–3 years), brain cell inflammation can be demonstrated as the cause of dementia. METHODS: This is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer's disease. The patient took Aricept for the treatment of Alzheimer's disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018. RESULTS: The patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons. CONCLUSIONS: This finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer's disease.
format Online
Article
Text
id pubmed-7011720
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-70117202020-03-10 Recovery of Dementia Syndrome following Treatment of Brain Inflammation Lee, Jong-hoon Choi, Su-hee Lee, Chul Joong Oh, Sang-suk Dement Geriatr Cogn Dis Extra Research Article AIM/BACKGROUND: This research aims to prevent progression from mild cognitive impairment (MCI) to Alzheimer's disease. A Japanese study of leprosy patients revealed that the incidence of dementia in leprosy patients was lower than that in patients taking dapsone who had never been treated. But a similar study the following year refuted the finding of less dementia in leprosy patients taking dapsone. According to conflicting reports, Mycobacterium leprae was a factor in reducing the incidence of Alzheimer's disease. Thus, we formed a hypothesis that if dapsone is administered to patients without leprosy but with MCI and the prophylactic effect of dementia syndrome is observed over a long period of time, we can determine whether dapsone can prevent the progression of MCI to dementia syndrome. If dementia does not occur after treating inflammation in brain cells while dementia develops after a certain long-term period (usually within 2–3 years), brain cell inflammation can be demonstrated as the cause of dementia. METHODS: This is a prospective cohort research. We report on an elderly patient diagnosed with MCI from February 2008 to January 2019. The patient took dapsone 100 mg once a day from 2010 to 2015 for the treatment of MCI. Since 2016, the production of dapsone has ceased in Korea. In June 2018, the patient was diagnosed with Alzheimer's disease. The patient took Aricept for the treatment of Alzheimer's disease but complained of serious side effects. And dapsone was re-administered to the patient from November 2018. RESULTS: The patient recovered to MCI and improved her daily life owing to the treatment with dapsone. The drug controls the inflammatory response in the brain, irrespective of whether proteins are deposited in neurons. CONCLUSIONS: This finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can treat inflammation in neurons and prevent and treat dementia syndrome, including Alzheimer's disease. S. Karger AG 2020-01-21 /pmc/articles/PMC7011720/ /pubmed/32158462 http://dx.doi.org/10.1159/000504880 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.
spellingShingle Research Article
Lee, Jong-hoon
Choi, Su-hee
Lee, Chul Joong
Oh, Sang-suk
Recovery of Dementia Syndrome following Treatment of Brain Inflammation
title Recovery of Dementia Syndrome following Treatment of Brain Inflammation
title_full Recovery of Dementia Syndrome following Treatment of Brain Inflammation
title_fullStr Recovery of Dementia Syndrome following Treatment of Brain Inflammation
title_full_unstemmed Recovery of Dementia Syndrome following Treatment of Brain Inflammation
title_short Recovery of Dementia Syndrome following Treatment of Brain Inflammation
title_sort recovery of dementia syndrome following treatment of brain inflammation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011720/
https://www.ncbi.nlm.nih.gov/pubmed/32158462
http://dx.doi.org/10.1159/000504880
work_keys_str_mv AT leejonghoon recoveryofdementiasyndromefollowingtreatmentofbraininflammation
AT choisuhee recoveryofdementiasyndromefollowingtreatmentofbraininflammation
AT leechuljoong recoveryofdementiasyndromefollowingtreatmentofbraininflammation
AT ohsangsuk recoveryofdementiasyndromefollowingtreatmentofbraininflammation